Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 79

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 79
---
 any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees,
members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment
agreements with our key employees, these employment agreements provide for at-will employment, which means that, except with regards to
compliance with relevant notice periods contained therein, any of our employees could leave our employment at any time. Our success also
depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior,
mid-level and senior scientific and medical personnel.

We will need to grow the size of our organization,
and we may experience difficulties in managing this growth.

As our development and commercialization
plans and strategies develop, as our manufacturing operations expand and as we continue operating as a public company, we expect to need
additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to accommodate our
expanded operations. Future growth would impose significant added responsibilities on members of management, including:

  identifying, recruiting, integrating, maintaining and motivating additional employees;  

  managing our internal development efforts effectively, including the clinical and FDA review process for our product candidate and the manufacturing infrastructure required to produce our produ...  

  improving our operational, financial and management controls, reporting systems and procedures.  

Our future financial performance
and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth,
and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote
a substantial amount of time to managing these growth activities.

We currently rely, and for
the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide
certain services, including certain aspects of regulatory approval, clinical trial management and construction of manufacturing facilities.
There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us
on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced
activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may
be extended, delayed or terminated, and we may not be able to obtain regulatory approval or certification of our Alpha DaRT technology
or other future products or product candidates or otherwise advance